Shortening the Ex Vivo Culture of CD19‐specific CAR T‐cells Retains Potent Efficacy Against Acute Lymphoblastic Leukemia Without CRES or Severe CRS

American Journal of Hematology - United States
doi 10.1002/ajh.25630
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Wiley

Related search

Potent Anti-Leukemia Activities of Humanized CD19-targeted CAR-T Cells in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

American Journal of Hematology
Hematology
2018English

CAR T Cells for Acute Lymphoblastic Leukemia

American Journal of Hematology
Hematology
2019English

CAR-T Cells: An Innovative Therapeutic Strategy Against Pediatric Acute Lymphoblastic Leukemia

Research in Molecular Medicine (RMM)
2019English

Locally Produced CD19 CAR T Cells Leading to Clinical Remissions in Medullary and Extramedullary Relapsed Acute Lymphoblastic Leukemia

American Journal of Hematology
Hematology
2018English

CD19 CAR-Targeted T Cells Induce Long-Term Remission and B Cell Aplasia in an Immunocompetent Mouse Model of B Cell Acute Lymphoblastic Leukemia

PLoS ONE
Multidisciplinary
2013English

CD19-Targeted Nanodelivery of Doxorubicin Enhances Therapeutic Efficacy in B-Cell Acute Lymphoblastic Leukemia

Molecular Pharmaceutics
Drug DiscoveryMolecular MedicinePharmaceutical Science
2015English

Immunotoxins Against CD19 and CD22 Are Effective in Killing Precursor-B Acute Lymphoblastic Leukemia Cells in Vitro

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2000English

Role of CAR-T Cell Therapy in B-Cell Acute Lymphoblastic Leukemia

Memo - Magazine of European Medical Oncology
OncologyHematology
2019English

Efficacy and Safety of Humanized Anti-Cd19-Car-T Therapy Following Intensive Lymphodepleting Chemotherapy for Refractory/Relapsed B Acute Lymphoblastic Leukaemia

British Journal of Haematology
Hematology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy